Pharmaceutical innovation in Eurasia: AstraZeneca registers a new medicine in Russia

AstraZeneca has registered Baxfendi (baxdrostat) in Russia for the treatment of arterial hypertension. The medicine has been approved as an add-on therapy for patients whose blood pressure remains insufficiently controlled despite treatment with three or more antihypertensive medicines.

Arterial hypertension is the most common modifiable risk factor for cardiovascular disease and affects approximately 1.4 billion people worldwide. According to WHO estimates, around 42.6 million people aged 30–79 in Russia live with hypertension, while only about 8.5 million achieve adequate blood pressure control despite treatment. This substantial unmet medical need highlights the importance of developing new therapeutic approaches for patients whose hypertension remains difficult to manage.

Baxdrostat represents a new class of antihypertensive therapy. It is a first-in-class aldosterone synthase inhibitor designed to directly suppress the production of aldosterone — a hormone involved in blood pressure regulation, elevated levels of which can make hypertension more difficult to control and contribute to cardiovascular and kidney risks. This mechanism offers a new therapeutic approach for patients with uncontrolled or resistant hypertension, for whom existing treatment options may be insufficient.

The clinical potential of the medicine was demonstrated in the international Phase III BaxHTN trial involving 796 patients with uncontrolled or resistant hypertension. After 12 weeks of treatment, patients receiving 2 mg of baxdrostat experienced an average reduction in systolic blood pressure of 15.7 mmHg from baseline, with a placebo-adjusted difference of 9.8 mmHg. The medicine was approved by the U.S. FDA in May 2026 and subsequently received Russian marketing authorization on August 31, 2026.

From an intellectual property perspective, the development is also indicative of a broader trend: international pharmaceutical companies continue to commercialize innovative products in Russia while relying on the available mechanisms for the protection of intellectual property rights.

The pharmaceutical sector remains one of the most IP-intensive industries. The development of a new medicine typically involves substantial investment in research, pre-clinical and clinical studies, manufacturing technologies and regulatory procedures. Effective protection of the resulting intellectual assets therefore remains an important part of the overall commercialization strategy.

For pharmaceutical and life sciences companies, a comprehensive IP strategy may cover patents relating to active compounds, formulations, dosage forms, therapeutic applications and manufacturing processes, alongside trademark and other forms of intellectual property protection.

For international rights holders, such protection is increasingly considered as part of a broader regional portfolio rather than on a jurisdiction-by-jurisdiction basis.

The Eurasian patent system remains an important route for obtaining patent protection across the region. The Eurasian Patent Organization currently comprises eight member states — Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan — allowing applicants to pursue regional patent protection through a centralized procedure.

For companies planning to manufacture, license or commercialize technologies across Eurasian markets, the Eurasian route can therefore form an important part of a coordinated international filing strategy.

Our practice supports clients in developing and implementing intellectual property strategies throughout the Eurasian region, from filing and prosecution to portfolio management, maintenance and enforcement of IP rights.

For pharmaceutical and technology companies in particular, early planning is critical. Decisions made before disclosure, market entry or commercial negotiations can have a significant impact on the scope, value and enforceability of future intellectual property rights.

If you have any questions or require assistance in obtaining IP protection through the EAPO system, please do not hesitate to contact us at info@patentica.com.